Cargando…

Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013

Background: Medical abortion with mifepristone and misoprostol was introduced in Norway in 1998, and since then there has been an almost complete change from predominantly surgical to medical abortions. We aimed to describe the medical abortion implementation process, and to compare characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Løkeland, Mette, Bjørge, Tone, Iversen, Ole-Erik, Akerkar, Rupali, Bjørge, Line
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837406/
https://www.ncbi.nlm.nih.gov/pubmed/28031316
http://dx.doi.org/10.1093/ije/dyw270
_version_ 1783304102638256128
author Løkeland, Mette
Bjørge, Tone
Iversen, Ole-Erik
Akerkar, Rupali
Bjørge, Line
author_facet Løkeland, Mette
Bjørge, Tone
Iversen, Ole-Erik
Akerkar, Rupali
Bjørge, Line
author_sort Løkeland, Mette
collection PubMed
description Background: Medical abortion with mifepristone and misoprostol was introduced in Norway in 1998, and since then there has been an almost complete change from predominantly surgical to medical abortions. We aimed to describe the medical abortion implementation process, and to compare characteristics of women obtaining medical and surgical abortion. Methods: Information from all departments of obstetrics and gynaecology in Norway on the time of implementation of medical abortion and abortion procedures in use up to 12 weeks of gestation was assessed by surveys in 2008 and 2012. We also analysed data from the National Abortion Registry comprising 223 692 women requesting abortion up to 12 weeks of gestation during 1998–2013. Results: In 2012, all hospitals offered medical abortion, 84.4% offered medical abortion at 9–12 weeks of gestation and 92.1% offered home administration of misoprostol. The use of medical abortion increased from 5.9% of all abortions in 1998 to 82.1% in 2013. Compared with women having a surgical abortion, women obtaining medical abortion had higher odds for undergoing an abortion at 4–6 weeks (adjusted OR 2.33; 95% confidence interval 2.28-2.38). Waiting time between registered request for an abortion until termination was reduced from 11.3 days in 1998 to 7.3 days in 2013. Conclusions: Norwegian women have gained access to more treatment modalities and simplified protocols for medical abortion. At the same time they obtained abortions at an earlier gestational age and the waiting time has been reduced.
format Online
Article
Text
id pubmed-5837406
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58374062018-03-09 Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013 Løkeland, Mette Bjørge, Tone Iversen, Ole-Erik Akerkar, Rupali Bjørge, Line Int J Epidemiol Women’s Health Background: Medical abortion with mifepristone and misoprostol was introduced in Norway in 1998, and since then there has been an almost complete change from predominantly surgical to medical abortions. We aimed to describe the medical abortion implementation process, and to compare characteristics of women obtaining medical and surgical abortion. Methods: Information from all departments of obstetrics and gynaecology in Norway on the time of implementation of medical abortion and abortion procedures in use up to 12 weeks of gestation was assessed by surveys in 2008 and 2012. We also analysed data from the National Abortion Registry comprising 223 692 women requesting abortion up to 12 weeks of gestation during 1998–2013. Results: In 2012, all hospitals offered medical abortion, 84.4% offered medical abortion at 9–12 weeks of gestation and 92.1% offered home administration of misoprostol. The use of medical abortion increased from 5.9% of all abortions in 1998 to 82.1% in 2013. Compared with women having a surgical abortion, women obtaining medical abortion had higher odds for undergoing an abortion at 4–6 weeks (adjusted OR 2.33; 95% confidence interval 2.28-2.38). Waiting time between registered request for an abortion until termination was reduced from 11.3 days in 1998 to 7.3 days in 2013. Conclusions: Norwegian women have gained access to more treatment modalities and simplified protocols for medical abortion. At the same time they obtained abortions at an earlier gestational age and the waiting time has been reduced. Oxford University Press 2017-04 2016-12-19 /pmc/articles/PMC5837406/ /pubmed/28031316 http://dx.doi.org/10.1093/ije/dyw270 Text en © The Author 2016. Published by Oxford University Press on behalf of the International Epidemiological Association http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Women’s Health
Løkeland, Mette
Bjørge, Tone
Iversen, Ole-Erik
Akerkar, Rupali
Bjørge, Line
Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title_full Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title_fullStr Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title_full_unstemmed Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title_short Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013
title_sort implementing medical abortion with mifepristone and misoprostol in norway 1998–2013
topic Women’s Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837406/
https://www.ncbi.nlm.nih.gov/pubmed/28031316
http://dx.doi.org/10.1093/ije/dyw270
work_keys_str_mv AT løkelandmette implementingmedicalabortionwithmifepristoneandmisoprostolinnorway19982013
AT bjørgetone implementingmedicalabortionwithmifepristoneandmisoprostolinnorway19982013
AT iversenoleerik implementingmedicalabortionwithmifepristoneandmisoprostolinnorway19982013
AT akerkarrupali implementingmedicalabortionwithmifepristoneandmisoprostolinnorway19982013
AT bjørgeline implementingmedicalabortionwithmifepristoneandmisoprostolinnorway19982013